ClinicalTrials.gov
ClinicalTrials.gov Menu

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02245737
Recruitment Status : Terminated (An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility)
First Posted : September 22, 2014
Last Update Posted : October 26, 2018
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 4, 2018
  Actual Study Completion Date : October 4, 2018